| 发明名称 | Formulations of 6-mercaptopurine | ||
| 摘要 | The present invention provides improved formulations of 6-mercaptopurine that exhibit better bioavailability and faster dissolution than previous formulations. | ||
| 申请公布号 | US9180097(B2) | 申请公布日期 | 2015.11.10 |
| 申请号 | US201414177037 | 申请日期 | 2014.02.10 |
| 申请人 | TEVA PHARMACEUTICAL INDUSTRIES LTD. | 发明人 | Lerner E. Itzhak;Flashner-Barak Moshe;v. Achthoven Erwin;Keegstra Hans;Smit Ruud |
| 分类号 | A61K31/33;A61K31/52;A61K31/522;A61K9/16 | 主分类号 | A61K31/33 |
| 代理机构 | Cooper & Dunham LLP | 代理人 | White John P.;Gershik Gary J.;Cooper & Dunham LLP |
| 主权项 | 1. A method of treatment of a subject afflicted with Crohn's disease which results in an improved side effect profile as compared to treatment of a subject afflicted by Crohn's disease by a standard formulation of 6-mercaptopurine (6-MP), the method comprising orally administering to the subject a compressed tablet consisting of 6-MP and one or more pharmaceutical carriers, which compressed tablet exhibits enhanced solubility in aqueous acid compared to the standard formulation of 6-MP and provides to the subject a therapeutic outcome with an improved side effect profile as compared to the treatment by the standard formulation of 6-MP. | ||
| 地址 | Petach-Tikva IL | ||